.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
FOURIER evaluated the PCSK9 inhibitor evolocumab in more than 27,000 patients with established atherosclerotic cardiovascular disease already receiving statin therapy. Evolocumab produced a profound reduction in LDL cholesterol and significantly reduced the risk of major cardiovascular events compared with placebo. The trial was important for demonstrating that additional LDL lowering beyond statin therapy can translate into incremental clinical benefit. For internists, the practical implication is that lipid management should be driven by overall ASCVD risk and achieved LDL-C rather than a binary decision about statin use. Patients with established disease who remain above individualized lipid targets may require combination therapy. Cost, access, adherence, injection preferences and absolute baseline risk all influence whether a PCSK9 inhibitor is appropriate. FOURIER also supports the concept that there is no obvious threshold at which further LDL reduction ceases to matter within the ranges studied. In routine practice, the first challenge remains consistent implementation of high-intensity statin therapy and verification of adherence before escalation.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
FOURIER evaluated the PCSK9 inhibitor evolocumab in more than 27,000 patients with established atherosclerotic cardiovascular disease already receiving statin therapy. Evolocumab produced a profound reduction in LDL cholesterol and significantly reduced the risk of major cardiovascular events compared with placebo. The trial was important for demonstrating that additional LDL lowering beyond statin therapy can translate into incremental clinical benefit. For internists, the practical implication is that lipid management should be driven by overall ASCVD risk and achieved LDL-C rather than a binary decision about statin use. Patients with established disease who remain above individualized lipid targets may require combination therapy. Cost, access, adherence, injection preferences and absolute baseline risk all influence whether a PCSK9 inhibitor is appropriate. FOURIER also supports the concept that there is no obvious threshold at which further LDL reduction ceases to matter within the ranges studied. In routine practice, the first challenge remains consistent implementation of high-intensity statin therapy and verification of adherence before escalation.
4 weeks back
A bioengineered oral nanozyme microsupplement converts pathological ROS into a protective polydopamine hydrogel shield. By curbing neutrophil extracellular traps and balancing T cells, this platform outperforms standard 5-ASA in preclinical colitis models, opening new paths for sustained remission.
2 days back
Recent research reveals that downregulating YAP1/TAZ-TEAD via Hippo signaling triggers spontaneous human trophoblast syncytialization in 3D cultures, illuminating placental biology and preeclampsia.
4 weeks back
Abdominal aortic aneurysm rupture remains a catastrophic vascular emergency. Groundbreaking research reveals that USP53 accelerates aneurysm progression by reprogramming smooth muscle cell metabolism toward aerobic glycolysis, highlighting a promising target beyond conventional diameter-based surveillance.
3 days back
A breakthrough study leverages natural language processing to accurately identify incident medication-related osteonecrosis of the jaw and track antiresorptive drug holidays from clinical narratives in electronic health records, advancing osteoporosis pharmacovigilance and dental safety.
3 days back
Recent research defines ferro-aging as a conserved iron-lipid axis driving organ decline across primates. Age-related iron dyshomeostasis stimulates ACSL4-mediated lipid peroxidation, promoting cellular senescence. Notably, vitamin C directly inhibits ACSL4, suppressing phospholipid oxidation and multi-organ decay.
4 days back
